Flucloxacillin

Flucloxacillin

Clinical data
Pregnancy category	AU: B1
Routes of administration	Oral, IM, IV, intrapleural, intraarticular
ATC code	J01CF05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Hepatic
Elimination half-life	0.75–1 hour
Excretion	Renal
Identifiers
IUPAC name 6-((S)-3-(2-chloro-6-fluorophenyl)-5-methylisoxazole- 4-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid
CAS Number	5250-39-5
PubChem CID	21319
DrugBank	APRD00609
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H17ClFN3O5S
Molar mass	453.87 g/mol

WikiDoc Resources for Flucloxacillin
Articles
Most recent articles on Flucloxacillin Most cited articles on Flucloxacillin Review articles on Flucloxacillin Articles on Flucloxacillin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Flucloxacillin Images of Flucloxacillin Photos of Flucloxacillin Podcasts & MP3s on Flucloxacillin Videos on Flucloxacillin
Evidence Based Medicine
Cochrane Collaboration on Flucloxacillin Bandolier on Flucloxacillin TRIP on Flucloxacillin
Clinical Trials
Ongoing Trials on Flucloxacillin at Clinical Trials.gov Trial results on Flucloxacillin Clinical Trials on Flucloxacillin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Flucloxacillin NICE Guidance on Flucloxacillin NHS PRODIGY Guidance FDA on Flucloxacillin CDC on Flucloxacillin
Books
Books on Flucloxacillin
News
Flucloxacillin in the news Be alerted to news on Flucloxacillin News trends on Flucloxacillin
Commentary
Blogs on Flucloxacillin
Definitions
Definitions of Flucloxacillin
Patient Resources / Community
Patient resources on Flucloxacillin Discussion groups on Flucloxacillin Patient Handouts on Flucloxacillin Directions to Hospitals Treating Flucloxacillin Risk calculators and risk factors for Flucloxacillin
Healthcare Provider Resources
Symptoms of Flucloxacillin Causes & Risk Factors for Flucloxacillin Diagnostic studies for Flucloxacillin Treatment of Flucloxacillin
Continuing Medical Education (CME)
CME Programs on Flucloxacillin
International
Flucloxacillin en Espanol Flucloxacillin en Francais
Business
Flucloxacillin in the Marketplace Patents on Flucloxacillin
Experimental / Informatics
List of terms related to Flucloxacillin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Flucloxacillin (INN) or floxacillin (USAN) is a narrow spectrum beta-lactam antibiotic of the penicillin class. It is used to treat infections caused by susceptible Gram-positive bacteria. Notably, it is active against beta-lactamase-producing organisms such as Staphylococcus aureus, which would otherwise be resistant to most penicillins. It is very similar to dicloxacillin and these two agents are considered interchangeable. Flucloxacillin is available under a variety of trade names including Flopen (CSL) and Floxapen (GSK).

Mode of action

Main article: Beta-lactam antibiotic

Like other β-lactam antibiotics, flucloxacillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria.

Medicinal chemistry

Flucloxacillin is insensitive to beta-lactamase (also known as penicillinase) enzymes secreted by many penicillin-resistant bacteria. The presence of the isoxazolyl group on the side chain of the penicillin nucleus facilitates the β-lactamase resistance, since they are relatively intolerant of side-chain steric hindrance. Thus it is able to bind to penicillin binding proteins (PBPs) and inhibit peptidoglycan crosslinking, but is not bound by or inactivated by β-lactamases.

Clinical use

Flucloxacillin is more acid-stable than many other penicillins and can be given orally, in addition to parenteral routes. However, like methicillin, it is less potent than benzylpenicillin against non-β-lactamase-producing Gram-positive bacteria.

Flucloxacillin has similar pharmacokinetics, antibacterial activity and indications to dicloxacillin and the two agents are considered interchangeable. It is believed to have higher incidence of severe hepatic adverse effects than dicloxacillin, but a lower incidence of renal adverse effects.

Available forms

Flucloxacillin is commercially available as the sodium salt flucloxacillin sodium, in capsules (250 or 500 mg), oral suspensions (125 mg/5 mL or 250 mg/5 mL), and injections (powder for reconstitution, 250, 500 and 1000 mg per vial).

Indications

Flucloxacillin is indicated for the treatment of infections caused by susceptible bacteria. Specific approved indications include:

• Staphylococcal skin infections and cellulitis – including impetigo, otitis externa, folliculitis, boils, carbuncles, and mastitis
• Pneumonia (adjunct)
• Osteomyelitis, septic arthritis
• Septicaemia
• Empirical treatment for endocarditis
• Surgical prophylaxis

Flucloxacillin has relatively poor activity, as noted above, against non-β-lactamase-producing bacteria including Streptococcus pyogenes. Therefore empirical therapy for significant cellulitis often involves dual-therapy to cover both staphylococci and streptococci, using either penicillin or ampicillin in addition to flucloxacillin. The latter is available as a standardised combination preparation co-fluampicil (flucloxacillin+ampicillin).

Precautions/contraindications

Flucloxacillin is contraindicated in those with a previous history of allergy to penicillins, cephalosporins or carbapenems. It should also not be used in the eye, or those with a history of cholestatic hepatitis associated with the use of dicloxacillin or flucloxacillin.

It should be used with caution in the elderly, patients with renal impairment, where a reduced dose is required; and those with hepatic impairment, due to the risk of cholestatic hepatitis.

Adverse effects

Common adverse drug reactions (ADRs) associated with the use of flucloxacillin include: diarrhoea, nausea, rash, urticaria, pain and inflammation at injection site, superinfection (including candidiasis), allergy, and transient increases in liver enzymes and bilirubin.

Rarely, cholestatic jaundice (also referred to as cholestatic hepatitis) has been associated with flucloxacillin therapy. The reaction may occur up to several weeks after treatment has stopped, and takes weeks to resolve. The estimated incidence is 1 in 15,000 exposures, and is more frequent in people >55 years, females, and those with treatment longer than 2 weeks.

Resistance

Despite flucloxacillin being insensitive to beta-lactamases, some organisms have developed resistance to it and other narrow-spectrum β-lactam antibiotics including methicillin. Such organisms include methicillin-resistant Staphylococcus aureus (MRSA).

See also

• Beta-lactam antibiotic
• Dicloxacillin